selected publications
-
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Blood.
2018
Academic Article
GET IT
Times cited: 158 -
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Neuro-oncology.
2017
Academic Article
GET IT
Times cited: 22 -
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 283 -
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
Journal of neuro-oncology.
2016
Academic Article
GET IT
Times cited: 40 -
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 87 -
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
Neuro-oncology.
2015
Academic Article
GET IT
Times cited: 147 -
Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
Neuro-oncology.
2015
Academic Article
GET IT
Times cited: 27 -
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Journal of neuro-oncology.
2015
Academic Article
GET IT
Times cited: 101 -
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Neuro-oncology.
2015
Academic Article
GET IT
Times cited: 43 -
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Academic Article
GET IT
Times cited: 68 -
Benign brain tumors and tumors associated with phakomatoses.
Continuum (Minneapolis, Minn.).
2015
Information Resource
GET IT
Times cited: 5 -
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Blood.
2015
Academic Article
GET IT
Times cited: 247 -
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Journal of neurosurgery.
2015
Information Resource
GET IT
Times cited: 435 -
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Neurology.
2014
Academic Article
GET IT
Times cited: 87 -
Whole-brain radiotherapy in patients with brain metastases from melanoma.
CNS oncology.
2014
Academic Article
GET IT
Times cited: 15 -
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2014
Academic Article
GET IT
Times cited: 82 -
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Neuro-oncology.
2014
Academic Article
GET IT
Times cited: 195 -
Bevacizumab for acute neurologic deterioration in patients with glioblastoma.
CNS oncology.
2013
Academic Article
GET IT
Times cited: 6 -
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Neuro-oncology.
2012
Academic Article
GET IT
Times cited: 88 -
Atypical and anaplastic meningiomas treated with bevacizumab.
Journal of neuro-oncology.
2012
Academic Article
GET IT
Times cited: 105